Mepolizumab —a novel option for the treatment of hypereosinophilic syndrome in childhood

ConclusionsAnti‐IL‐5 antibodies, which can be applied without substantial drug intolerances, are a new, safe, and effective treatment option for pediatric patients with hypereosinophilic syndrome.

Source: Pediatric Allergy and Immunology - November 28, 2017 Category: Allergy & Immunology Authors: Carsten Schwarz, Thilo M üller, Susanne Lau, Kirn Parasher, Doris Staab, Ulrich Wahn Tags: ORIGINAL ARTICLE Source Type: research